Search Results

Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.

• Authors : D'Erasmo L; Department of Translational and Precision Medicine, Sapienza University of Rome , Rome, Italy.; Cardiovascular Prevention Unit, Department of Endocrinology and Metabolism, Pitié-Salpêtrière University Hospital , Paris, France.

Subjects: Apolipoprotein C-III/Apolipoprotein C-III/Apolipoprotein C-III/*antagonists & inhibitors ; Hypertriglyceridemia/Hypertriglyceridemia/Hypertriglyceridemia/*drug therapy ; Oligonucleotides/Oligonucleotides/Oligonucleotides/*therapeutic use Familial hyperchylomicronemia syndrome

• Source: Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Oct; Vol. 21 (14), pp. 1675-1684. Date of Electronic Publication: 2020 Jul 10.Publisher: Informa Healthcare Country of Publication: England NLM ID: 100897346 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals.

• Authors : Yamamoto R; Sacks FM ...

Subjects: Carotid Intima-Media Thickness*; Apolipoprotein C-III/Apolipoprotein C-III/Apolipoprotein C-III/*blood ; Biomarkers/Biomarkers/Biomarkers/*blood

• Source: Atherosclerosis [Atherosclerosis] 2018 Feb; Vol. 269, pp. 92-99. Date of Electronic Publication: 2018 Jan 02.Publisher: Elsevier Country of Publication: Ireland NLM ID: 0242543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1484

Record details

Volanesorsen: First Global Approval.

• Authors : Paik J; Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. .; Duggan S

Subjects: Apolipoprotein C-III/Apolipoprotein C-III/Apolipoprotein C-III/*antagonists & inhibitors ; Oligonucleotides/Oligonucleotides/Oligonucleotides/*therapeutic use ; Oligonucleotides, Antisense/Oligonucleotides, Antisense/Oligonucleotides, Antisense/*therapeutic useFamilial hyperchylomicronemia syndrome

• Source: Drugs [Drugs] 2019 Aug; Vol. 79 (12), pp. 1349-1354.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print Cited Medium: Internet ISSN:

Record details

APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups.

• Authors : Goyal S; Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., Rm 317 BMSB, Oklahoma City, OK, 73104, USA.; Tanigawa Y

Subjects: Genetic Variation*; Apolipoprotein C-III/Apolipoprotein C-III/Apolipoprotein C-III/*genetics ; Coronary Artery Disease/Coronary Artery Disease/Coronary Artery Disease/*genetics

• Source: Lipids in health and disease [Lipids Health Dis] 2021 Sep 21; Vol. 20 (1), pp. 113. Date of Electronic Publication: 2021 Sep 21.Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X

Record details

Genome-wide linkage analysis for human longevity: Genetics of Healthy Aging Study.

• Authors : Beekman M; Blanché H ...

Subjects: Genetic Loci*; Apolipoprotein C-I/Apolipoprotein C-I/Apolipoprotein C-I/*genetics ; Apolipoproteins E/Apolipoproteins E/Apolipoproteins E/*genetics

• Source: Aging cell [Aging Cell] 2013 Apr; Vol. 12 (2), pp. 184-93. Date of Electronic Publication: 2013 Feb 06.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101130839 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk.

• Authors : Moore LE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852, USA. ; Brennan P

Subjects: Apolipoprotein C-I/Apolipoprotein C-I/Apolipoprotein C-I/*genetics ; Apolipoproteins E/Apolipoproteins E/Apolipoproteins E/*genetics ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*genetics

• Source: Cancer research [Cancer Res] 2009 Oct 15; Vol. 69 (20), pp. 8001-8. Date of Electronic Publication: 2009 Oct 06.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium:

Record details

Common genetic variants of lipoprotein lipase and apolipoproteins AI-CIII that relate to coronary artery disease: a study in Chinese and European subjects.

• Authors : Zhang Q; Department of Metabolism and Genetics, St. Bartholomew's Hospital, London, EC1A 7BE, United Kingdom.; Liu Y

Subjects: Gene Frequency* ; Genetic Variation*; Apolipoprotein A-I/Apolipoprotein A-I/Apolipoprotein A-I/*genetics

• Source: Molecular genetics and metabolism [Mol Genet Metab] 1998 Jul; Vol. 64 (3), pp. 177-83.Publisher: Academic Press Country of Publication: United States NLM ID: 9805456 Publication Model: Print Cited Medium: Print ISSN: 1096-7192

Record details

Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

• Authors : van Capelleveen, Julian C.; Lee, Sang-Rok; Verbeek, Rutger

Subjects: CORONARY heart disease risk factors; LIPID analysis; CORONARY diseaseEUROPE

• Source: Journal of Clinical Lipidology; Nov2018, Vol. 12 Issue 6, p1493-1493, 1p

Record details

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.

• Authors : Launonen V; Department of Clinical Genetics, University of Oulu/Oulu University Hospital, Finland.; Laake K

Subjects: Chromosomes, Human, Pair 11* ; Loss of Heterozygosity*; Apolipoproteins C/Apolipoproteins C/Apolipoproteins C/*genetics

• Source: British journal of cancer [Br J Cancer] 1999 May; Vol. 80 (5-6), pp. 879-82.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

Record details

Arrowhead presents positive new Phase 1/2 clinical data on cardiometabolic candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020.

• Source: Chemical Business NewsBase (UK), August 31, 2020, 2pp

Record details